ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,118.71
0.53%
Dow Jones
44,565.07
0.00%
US Dollar vs MXN
20.22517
-0.78%
Brent Oil
78.095
0.99%
Bitcoin
105,164.40
1.15%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) Noticias

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RXRX
FechaHoraFuenteTítuloSímboloCompañía
17/01/202516:58PR Newswire (US)Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028NASDAQ:RXRXRecursion Pharmaceuticals Inc
17/01/202516:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/01/202516:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/01/202508:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
07/01/202508:15GlobeNewswire Inc.Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/01/202507:30GlobeNewswire Inc.Recursion to Present at 43rd Annual JP Morgan Healthcare ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/12/202415:05GlobeNewswire Inc.Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/12/202416:05Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/12/202417:00GlobeNewswire Inc.Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/12/202407:30GlobeNewswire Inc.Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and LymphomaNASDAQ:RXRXRecursion Pharmaceuticals Inc
02/12/202418:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
27/11/202415:09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
20/11/202406:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/11/202406:00GlobeNewswire Inc.Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/11/202408:08GlobeNewswire Inc.Recursion and Exscientia Shareholders Approve the Proposed CombinationNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/11/202415:54GlobeNewswire Inc.Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model GardenNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/11/202413:17Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202415:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202415:15GlobeNewswire Inc.Recursion Provides Business Updates and Reports Third Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202405:12Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
30/10/202407:22GlobeNewswire Inc.Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6thNASDAQ:RXRXRecursion Pharmaceuticals Inc
22/10/202407:00GlobeNewswire Inc.Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infectionNASDAQ:RXRXRecursion Pharmaceuticals Inc
10/10/202405:00Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:RXRXRecursion Pharmaceuticals Inc
02/10/202407:00GlobeNewswire Inc.Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and LymphomaNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/09/202405:03Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/09/202407:00GlobeNewswire Inc.Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/08/202404:44IH Market NewsTSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202413:41GlobeNewswire Inc.CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202406:39GlobeNewswire Inc.Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End CapabilitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202406:30GlobeNewswire Inc.Recursion Provides Business Updates and Reports Second Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX

Su Consulta Reciente

ASX
CLI
CropLogic
TG
A2RUAZ
Allergan Funding Scs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados